SCHEMBL13702248

SCHEMBL13702248

C#CCO[C@@H]1OC(CO)[C@@H](O[C@@H]2OC(CO)[C@H](O)C(O[C@H]3OC(CO)[C@H](O)C(O)C3O)C2O)C(O)C1NC(C)=O

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 7/20 0.63
▸ LGALS8 O00214 2/20 0.63
▸ LGALS4 P56470 2/20 0.63
▸ MAPK1 P28482 2/20 0.48
▸ CD69 Q07108 1/20 0.46
▸ CHIA Q9BZP6 1/20 0.46
▸ LGALS1 P09382 1/20 0.45
▸ LGALS7; LGALS7B P47929 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ LGALS9 O00182 1/20 0.44
▸ FGF1 P05230 1/20 0.41
▸ FGF2 P09038 1/20 0.41
▸ VEGFA P15692 1/20 0.41
▸ HPSE Q9Y251 1/20 0.41
▸ SELL P14151 1/20 0.41
▸ CD209 Q9NNX6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14530114 1.00 LGALS3 (0.63) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL12792627 0.97 LGALS3 (0.67) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL13849178 0.92 LGALS3 (0.59) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL18122370 0.86 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL25868457 0.86 MAPK1 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL12792638 0.86 MAPK1 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL13849179 0.86 MAPK1 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL23613765 0.85 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL26334737 0.85 LGALS3 (0.64) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL22360317 0.84 LGALS3 (0.80) LGALS3LGALS8LGALS4MAPK1CD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357671-B2 High affinity Siglec ligands Paulson, James (US) 2013-01-22 — — US disclosed
US-20090238837-A1 High Affinity Siglec Ligands NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090238837-A1 High Affinity Siglec Ligands SIGLEC7, SIGLEC9, FCGR1A LGALS3 55/4885LGALS8 63/4885LGALS4 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback